 |
Perspectives
and Opinions provides in-depth, critical analyses of new publications,
conference reports, and breaking news from the worlds of antiretroviral
drug research and HIV clinical care.
Designed to deliver important
new research findings to the practicing clinician, each feature article
contains pertinent background information and an emphasis on practical
implications. New Perspectives and Opinions, authored by our Advisory
Board members, are added each month.
|
|
Therapeutic Decision Making Based on Antiretroviral Drug Resistance Testing: Are We There Yet?
Dr. Brian Conway provides an introduction to this edition's new articles on the recent VIRADAPT and GART studies.
Improving HIV Therapy with Drug Resistance Genotyping: The VIRADAPT Study
Dr. Jonathan Schapiro reviews the results of the first prospective trial of the utility of genotypic resistance testing in tailoring new treatment regimens for patients failing antiretroviral therapy. Results of the VIRADAPT study were presented at the 4th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland.
The Impact of Genotypic Antiretroviral Resistance Testing (GART) in Patients Failing Antiretroviral Therapy: CPCRA 046 (The GART Study)
Dr. Michelle Roland takes a close look at preliminary data from the GART study, the US counterpart to Europe's VIRADAPT study, presented by HIVresistanceWeb.com's own Dr. Douglas Mayers at the 6th Conference on Retroviruses and Opportunistic Infections in Chicago.
Primary Infection, Primary Resistance
Dr. David Katzenstein discusses the growing problem of primary antiretroviral drug resistance in light of recent prevalence studies presented at the 6th Conference on Retroviruses and Opportunistic Infections in Chicago and earlier reports from the 2nd International Workshop on HIV Drug Resistance & Treatment Strategies in Lake Maggiore, Italy.
Update on Efavirenz
Dr. Robert Shafer reviews new efavirenz-related data presented at the 6th Conference on Retroviruses and Opportunistic Infections in Chicago.
Expert Systems for HIV Resistance Assays
Dr. Jonathan Schapiro explores the development of computer-based expert systems for interpreting genotypic resistance test results.
|
